EKF Diagnostics Holdings PLC New data published on PointMan
18 Septembre 2015 - 8:00AM
RNS Non-Regulatory
TIDMEKF
EKF Diagnostics Holdings PLC
18 September 2015
18 September 2015
EKF Diagnostics Holdings plc
("EKF", the "Company")
New data published on PointMan(TM) molecular diagnostic
technology
EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed
point-of-care, central laboratory and molecular diagnostics
business, announces that two research posters supporting its
PointMan(TM) molecular diagnostic technology have been delivered at
key conferences.
On 8(th) September at the International Association for the
Study of Lung Cancer's 16th World Conference on Lung Cancer meeting
in Denver USA, Luecke et al from GILUPI GmbH and EKF Molecular
presented a poster titled: An effective in vivo Liquid Biopsy tool
for high yield isolation of circulating tumour cells. The
researchers used EKF's PointMan KRAS DNA enrichment technology to
analyse circulating tumour cells from blood samples taken from lung
cancer patients using the GILUPI CellCollector(R). The team
concluded that the combination overcomes blood volume limitations
of other CTC extraction approaches and mutations in isolated CTC
DNA can be analysed using the PointMan technology. The Gilupi
device allows CTC enumeration, molecular characterisation, and
biomarker expression analysis, which could help guide treatment
strategies and monitoring therapy efficacy.
PointMan also featured in a poster at the 9(th) Circulating
Nucleic Acid in Plasma and Serum meeting in Berlin where Kimura et
al from the Department of Respiratory Medicine, Kanazawa University
Hospital, Japan, presented data on T790M DNA enrichment of
specimens from a cohort of 52 lung cancer patients. T790M is an
important biomarker as its presences indicates patients are
becoming resistant to the drug regimen that is being used in the
treatment of their late stage lung cancer. Being able to
accurately, rapidly, cost effectively and non-invasively detect
EGFR T790M early will assist in informing clinicians that a change
in treatment is required. This poster expands on work previously
presented at AACR in April and concludes that the PointMan assay is
a useful and rapid technique for the detection of T790M in
circulating DNA.
Julian Baines, CEO of EKF Diagnostics said: "These posters
presented at two of the world's most prestigious meetings of
researchers and clinicians treating lung cancer confirm the utility
of PointMan and its key role in the molecular analysis of
circulating tumour cells and cancer DNA in liquid biopsies. The
global incidence of lung cancer is estimated at 1.825M of which 85%
are non-small cell lung cancer and relevant to the benefit that
using PointMan will offer by way of indicating more targeted and
effective treatment options for clinicians treating lung cancer in
the future. The increasing body of scientific data that is being
generated to support PointMan will be particularly important as we
commercialise the technology following CE regulatory approval
anticipated later this month."
In accordance with Rule 26.1 of the Takeover Code, a copy of
this announcement will be published on the Company's website
http://www.ekfdiagnostics.com by no later than 12 noon on 16
September 2015.
Enquiries:
EKF Diagnostics Holdings plc Tel: 029 2071 0570
David Evans, Executive Chairman Mob: 07740 084 452
Julian Baines, CEO Mob: 07788 420 859
Paul Foulger, CFO Mob: 07710 989 255
Panmure Gordon (UK) Limited Tel: 020 7886 2500
Robert Naylor (Corporate Finance)
Paul Fincham (Corporate Finance)
Walbrook PR Limited Tel: 020 7933 8780 or ekf@walbrookpr.com
Mike Wort Mob: 07900 608 002
Anna Dunphy Mob: 07876 741 001
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRALRMATMBABBAA
(END) Dow Jones Newswires
September 18, 2015 02:00 ET (06:00 GMT)
International Brand Licensing (LSE:IBL)
Graphique Historique de l'Action
De Avr 2024 à Mai 2024
International Brand Licensing (LSE:IBL)
Graphique Historique de l'Action
De Mai 2023 à Mai 2024
